Results 141 to 150 of about 94,542 (298)

Clinicians' and people who use drugs' perspectives on artificial intelligence in addiction medicine

open access: yesAddiction, EarlyView.
Abstract Background and aims Artificial intelligence (AI) may improve addiction medicine workflows and health outcomes but raises questions about data privacy and unintended harms for people who use drugs (PWUD). This qualitative study aimed to understand the perspectives of clinicians and PWUD regarding perceived benefits and concerns about clinical ...
Patrick J. A. Kelly   +6 more
wiley   +1 more source

The use of rotation to fentanyl in cancer-related pain

open access: yes, 2017
Delia Dima,1 Ciprian Tomuleasa,1 Ioana Frinc,1 Sergiu Pasca,2 Lorand Magdo,2 Ioana Berindan-Neagoe,2–4 Mihai Muresan,5 Cosmin Lisencu,5 Alexandru Irimie,5,6 Mihnea Zdrenghea1,7 1Department of Hematology, Ion Chiricuta Oncology Institute, 2Faculty ...
Tomuleasa C   +9 more
core  

A framework to determine naloxone saturation with simulation modeling and cost‐effectiveness methods

open access: yesAddiction, EarlyView.
Abstract Background and aims Jurisdictions lack practical tools to determine data‐informed naloxone saturation targets that account for local overdose dynamics and resource constraints. We aimed to introduce a generalizable framework that integrates simulation modeling with cost‐effectiveness principles to identify local naloxone saturation targets ...
Zongbo Li   +7 more
wiley   +1 more source

Methylenedioxymethamphetamine (MDMA)‐related fatal poisoning in Australia, 2016 to 2025: Trends, characteristics and toxicology

open access: yesAddiction, EarlyView.
Abstract Aims To determine: (1) Population rates of fatal methylenedioxymethamphetamine (MDMA)‐related poisoning over the period 2016–2023, years with high closure rates in the National Coronial Information System (NDIS); (2) the case characteristics of known cases of fatal MDMA‐related poisoning, 2016–2025; and (3) whether there have been changes in ...
Shane Darke   +5 more
wiley   +1 more source

"Risk Perception and Management of Fentanyl and Xylazine Abuse Among Drug Addicts in Northeastern Italy: Epidemiological Analysis, Clinical Impact, and Multidisciplinary Intervention Perspectives"

open access: yes
openQuesta tesi esplora l’abuso emergente di Fentanyl e Xilazina tra le persone con disturbo da uso di sostanze nel Nord-Est dell’Italia, con un focus specifico sulle province di Treviso e Preganziol.
DEI NEGRI, MARGHERITA
core  

Fentanyl Sensitization

open access: yes
Three experiments investigating the effects of repeated fentanyl on the locomotor response of adolescent (PD 33) and adult (PD 80) rats. We hypothesized that fentanyl like many other addictive drugs would increase the locomotor response after repeated ...
Crawford, Cynthia
core   +1 more source

The association between chronic pain and non‐fatal overdose in people who inject drugs: Longitudinal cohort study in Montreal, Canada, 2017 to 2025

open access: yesAddiction, EarlyView.
Abstract Background and aims The prevalence of chronic pain is elevated among people who inject drugs. Chronic pain may motivate drug use, potentially increasing the risk of non‐fatal overdose. We aimed to estimate the association between chronic pain and non‐fatal overdose in people who inject drugs.
Sarah Larney   +9 more
wiley   +1 more source

Clinical applications of wearable devices for individuals with at‐risk substance use and substance use disorders: A systematic review

open access: yesThe American Journal on Addictions, EarlyView.
Abstract Background and Objectives Managing substance use disorders (SUDs) is limited by the lack of longitudinal clinical data during active use and recovery. Wearable devices may help address this gap by capturing physiological and behavioral data in real‐world settings.
Alexandra Sas   +10 more
wiley   +1 more source

Updated EAACI Statement on Drug Hypersensitivity Skin Testing: Methodology and Non‐Irritative Concentrations

open access: yesAllergy, EarlyView.
ABSTRACT These updated EAACI guidelines aim to standardize skin testing methodologies for both immediate and non‐immediate drug hypersensitivity reactions. For immediate reactions, the optimal testing window is 4–6 weeks post‐reaction; whereas beyond 6 months, false‐negative results increase.
Annick Barbaud   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy